Negative TrendThe stock price has been going down consistently over the past 5 months; however new development indicate an expansion to human stem-cell research which would rocket the stock price if positive results are announced. Moreover, Geron is ranked in the top 5in the biotechnology patent scorecard published in the Feb. 12 issue of TheWall Street Journal.
As of now I don't see any reason for a strong buy, but if you are a risk taker and find something about this company that competitors don't have then go for it. And, if you already own it I don't suggest selling as it is close to its 52-week low.